4d Molecular Therapeutics In (FDMT) Smart Money Holdings (13F, Q2 2026)

FDMT ranks #3514 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

162 institutions disclose a position in FDMT, but none treat it as a major bet — even Acuta Capital Partners, LLC, its most concentrated holder, allocates just 4.7% of its own portfolio to it.

Assenagon Asset Management S.A. has added to its FDMT position for two straight quarters, increasing it by $416.7K to reach $1.2M today.

FDMT is down 5.7% today, but institutions show net buying of $151.1M this quarter — a divergence between today's price move and the underlying institutional flow.

FDMT reported a net loss of $179.2M over the trailing twelve months.

• Not yet profitable — net loss of $179.2M over the trailing twelve months
• Revenue grew 278712.1% year over year
• Net income improved year over year, from -$196.1M to -$179.2M
• Operating cash flow was negative, using $109.1M in cash
• Current ratio of 9.39x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range